NCT00771823

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

A Placebo Controlled Study of the Impact on Insulin Sensitivity and Lipid Profile of Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: St Stephens Aids Trust · Academic / Other
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

A placebo controlled study of the impact on insulin sensitivity and lipid profile of maraviroc 300 mg twice daily in HIV negative male volunteers.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Maraviroc	Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
DRUG	Maraviroc	* Placebo twice daily for the first 14 days of the study. * Maraviroc 300 mg twice daily for the last 14 days of the study.

Timeline

• Start date: 2008-05-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2008-10-15
• Last updated: 2010-08-16

Locations

1 site across 1 country: United Kingdom